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The M protein fibrils emanate from the surface of Streptococcus pyogenes cells as
a-helical coiled coils (1, 2) and render the organisms resistant to ingestion and killing
by phagocytic cells in the blood of the non-immune host. In the immune host, type-
specific antibodies against the M protein neutralize the antiphagocytic effect and
enable the rapid elimination of any invading streptococci bearing the same serotype
of M protein (3). Efforts to vaccinate against streptococcal infections have been
hampered by toxic reactions to almost any streptococcal product administered to
humans (4).
Recent studies have demonstrated protective and autoimmune epitopes within the
covalent structures of several M proteins (5-12). In an attempt to overcome toxicity
and autoimmune reactions, we investigated the protective immunogenicity of M pro-
teins cloned and expressed in an attenuated aroA strain ofSalmonella typhimurium SL3261,
which is able to invade the mucosal surfaces of the intestinal tract but is unable to
cause disease (13). We now report that immune responses can be obtained without
toxicity by the oral administration of the recombinant aroA S. typhimurium vaccine.
Our findings have bearing not only on the development of M protein vaccines to
protect against streptococcal infections triggering rheumatic fever and rheumatic
heart disease, but also on the development of vaccines in general, whereby an at-
tenuated orally administered infectious agent is used as a delivery vehicle to evoke
protective immunity against unrelated infectious agents.
Materials and Methods
BacterialStrains, Plasmids, and Growth Conditions.
￿
Serotype M5 S pyogenes strains Manfredo
and Smith, and M serotype 24 S. pyogenes strain Vaughn have been described previously (8,
9). S. typhimurium strains SL1344 (aro') and SL3261 (aroA- ) were a generous gift from Dr.
Bruce A. D. Stocker and his associatesat Stanford University, Stanford, CA (13). The S typhi-
murium strain LB5000 (r m') was kindly provided by Dr. Thomas F. Meyer, Max-Planck-
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Institute, Tubingen (14). The plasmid pMK207, containing the entire genome for the sero-
type 5 M protein, has been previously characterized by Kehoe et al. (15, 16). SL3261 was
transformed with pMK207 (which was obtained from S. typhimurium LB5000 harboring
pMK207) by a standard procedure (17). All pMK207 harboring bacterial strains (M5` and
Kan`) were maintained on nutrient agar containing 50 kg/ml kanamycin sulfate. The aroA-
SL3261 was maintained on nutrient agar containing 10 wg/ml each of paraminobenzoic acid
(PABA)' and 2,3-dihydroxybenzoic acid (DHB; Sigma Chemical Co., St. Louis, MO). Poly-
peptides of type 5 and 24 M proteins were extracted with pepsin and purified as described
(8). The extracts are designated pep M5 and pep M24.
Immunization ofMice.
￿
BALB/c mice were immunized orally with the pMK207-transformed
Salmonella SL3261. The organisms were grown as described above for 16 h at 37°C, harvested,
washed twice in PBS (0.02 M phosphate, 0.15 NaCl, pH 7.4), and resuspended in sufficient
PBS to give a concentration of N109 CFU per 25 wl. Mice were deprived of water for 24 h
and then fed 25-Al doses of the suspension on days 1 and 6. Serum was collected by cardiac
puncture at intervals of 1, 3, 5, 9, 10, 15, and 20 wk after immunization. In some experi-
ments, mice were given booster injections intraperitoneally with 50 wg of a pepsin extract
(8) of type 5 M protein (pep M5) in 0.1 ml of PBS, 60 h before bleeding.
Antibody Assays.
￿
M protein-specific antibodies were measured by ELISA and opsoniza-
tion assays and were performed as previously described (15). The test mixtures for the op-
sonophagocytic assays consisted of 25 g1 of a standard suspension of streptococci, 25 wl of
test serum, and 0.4 ml whole, heparinized (10 U/ml) human blood. After incubation by rota-
tion at 37 °C for 45 min, the percentage of neutrophils with associated streptococci (percent
opsonization) was estimated by microscopic counts of stained smears (15).
Salivary antibodies were assayed by ELISA using immobilized pep M5 as antigen and
serial dilutions of pooled saliva collected at 20 wk. Salivation was induced by injecting each
mouse intraperitoneally with 0.1 ml of 27o pilocarpine. In addition to assaying for IgG, the
saliva samples were also assayed for the presence of IgA and IgM by using the respective
class-specific, goat anti-rabbit antisera (Cappel Laboratories, Cochranville, PA).
Cell Fractionation.
￿
S. typhimurium SL3261 (pMK207) cells were cultured and fractionated
according to the methods described by Fischetti et al. (18). Each cellular compartment was
assayed for M protein by Western immunoblot analysis.
Transblot Analyses.
￿
Immunoelectrophoresis was performed in order to determine the sta-
bility of M5 protein expression in SL3261. The pMK207-expressing bacteria were grown
in 10 ml nutrient broth containing 10 ug/ml each of PABA and DHB and 50 ug/ml kanamycin
at 37°C for 16 h. The cells were harvested at 8,000 rpm for 15 min and washed thrice with
an equal volume of cold PBS in order to remove residual kanamycin. A 0.1-ml aliquot of
washed SL3261-pMK207 cells was inoculated into 9.9 ml of fresh nutrient broth containing
PABA and DHB but lacking kanamycin, and was incubated at 37'C for 16 h. The subcul-
turing of SL3261-pMK207 (using 17o inoculums) into media lacking kanamycin was repeated
four more times. At 16-h intervals, the remaining 9.9 ml of SL3261-pMK207 was pelleted
and prepared for immunoblot analysis of M5 protein as previously described (15).
Challenge Infection Experiments.
￿
Immunized and control BALB/c mice were challenged in-
traperitoneally with either the homologous M5 or heterologous M24 streptococci, or with
wild-type S typhimurium SL1344. The organisms were grown in Todd-Hewitt broth for 16
h at 37°C, collected, and washed three times in PBS, and finally resuspended to the desired
concentration in PBS. 22 d after the initial immunizing dose (see above), each mouse was
given intraperitoneal injections of 0.5 ml of bacterial suspension with various concentrations
of bacteria. Intrunasal challenge doses consisted of 10 pl of bacterial suspension per nostril
in lightly anesthetized mice (penthrane). Deaths were recorded over a period of 10 d. All
deaths by either route occurred between 2 and 6 d for animals challenged with streptococci
and between 5 and 7 d for those challenged with S. typhimurium . All surviving mice appeared
healthy up to 30 d after challenge.
Abbreviations used in this paper: DHB, 2,3-dihydroxybenzoic acid; PABA, paraminobenzoic acid.POIRIER ET AL .
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Results
The attenuated aroA strain of S typhimurium SL3261 developed by Hoiseth and
Stocker (13) was chosen as the delivery vehicle . This mutant strain exhibits nutri-
tional markers both forPABA andDHB (13) . TheM5 gene (spm5) was cloned and
expressed in Escherichia coli LE392 as described (15, 16). The plasmid pMK207 was
isolated, purified, and transformed first into an rm+ strain LB5000 ofS . typhimu-
rium (14, 17) . The plasmid isolated and purified from LB5000 was then used to trans-
form aroA S . typhimurtum SL3261 .
Expression ofM5 Protein by aroA S . typhimurium SL3261 .
￿
The transformed LB5000
and SL3261 expressed the entire M5 protein molecule as demonstrated byWestern
blot analysis ofwhole cell lysates (Fig. 1, lanes 1 and 2, respectively). The typical
triplet of M5 protein (see References 15 and 16) migrated as bands ofM r 57.9, 55.4,
and 52 .9 kD. The M5 protein was confined (>90%) to the cytoplasmic compart-
ment as demonstratedby spheroplasting ofthe transformed organisms . The absence
ofanyM protein on the surface of the organisms was shown by their failure to ag-
glutinate in the presence of antisera previously prepared against pepM5 (9) . The
M5 protein was expressed in a stable fashion by SL3261 even in the absence of an-
tibiotic pressure during repeated subcultures over 5 d, respresenting -35 genera-
tions of growth (Fig. 1, lanes 3-8) . Moreover, SL3261-pMK207 isolated from the
liver ofa mouse 3 wk after oral inoculation continued to express M5 protein (Fig .
1, lane 9) (see below) .
Mouse Tolerance of Transformed aroA S . typhimurium .
￿
BALB/c mice were fed orally
with increasing numbers ofSL3261-pMK207 todetermine the dose oftransformed
organisms the animals wouldtolerate . None of themice receivingup to amaximum
of 1.65 x 109CFU per oral dose either sickened or died . At 1, 3, 5, and 10 wk after
inoculation, two mice from each dosage group were killed, and their livers, gall
bladders, spleens, and intestines were cultured for SL3261-pMK207 on McConkey's
agar containing 50 gg/ml kanamycin sulfate and 10 pg/ml each ofPABA andDHB.
Non-lactose-fermenting colonies could be isolated only from the mice receiving 106
CFU or more at 1 wk and only from those receiving 109CFU ofSL3261-pMK207
at 3 wk. No isolates were recovered after 3 wk . The colonies isolated at 3 wk ex-
pressed intact M protein (Fig. 1, lane 9) .
Immune Responses in Mice.
￿
Based on the results obtained above, groups of mice
were immunized orally with 25-ltl suspensions of streptococci containing -109CFU
ofpMK207-transformed aroA organisms on day 1 and 6. Sera obtained at 1, 3, 5,
FIGURE 1 .
￿
Immunoblot analyses of type 5 M
protein expressed by pMK207-transformed S .
typhimurium LB5000 (lane 1) and SL3261 (lane
2) . Lanes 3-7 demonstrate the expression ofM
5 protein by SL3261-pMK207 after repeated sub-
culture in the absence ofkanamycin . Lane 8shows
M5 protein expressed by SL3261-pMK207 in the
presence ofkanamycinusing the fifth subculture
(lane 7) as the inoculum . Lane 9 represents M5
protein expressed by SL3261-pMK207 isolated
from the liver of BALB/c mice 3 wk after oral im-
munization .28 IMMUNITY EVOKED BY aroA SALMONELLA TYPHIMURIUM
TABLE I
Immune Responses in BALBIc Mice Orally Immunized with S. typhimurium SL3261pMK207
' All mouse antisera that reacted against immobilized pep M24 gave titers of <50.
Mice were boosted 60 h before bleed out with pep M5.
5 Both anti-pep M5 and anti-pep M24 antisera were prepared in rabbits.
II Theantibody titers for the rabbit anti-pep M5 or anti-pep M24antisera were not determined.
9, 10, 15, and 20 wk were pooled and examined for antibodies against type 5 M
protein and type 5 streptococci by ELISA and opsonization experiments, respec-
tively (Table I). The pooled, pilocarpine-stimulated salivas obtained 20 wk post-
immunization contained IgA antibodies against pep M5 in ELISA titers of 1:32
compared with preimmune titers of <1 :4 (Table II). 60 h after a booster injection
of 50 Itg of pep M5, the IgA anti-pep M5 titer was 1:64. There was a twofold in-
crease in antibody titerwhen saliva was reactedwith a mixtureof peroxidase labeled
anti-mouse IgA + IgG + IgM antisera (Table II). None of the serum or salivary
antibodies reacted with cardiac tissues by immunofluorescence tests (9) of frozen
sections ofhuman heart or with human heart sarcolemmal membrane polypeptides
in Western immunoblots (10, 15).
The absence of reactivity of the above immune sera with heart tissue, in light of
previous demonstrations of the presence of such crossreactive antibodies in rabbits
immunized with a polypeptide fragment of type 5 M protein (9, 10), prompted the
immunization of four BALB/c mice with pep M5 protein (50 t1g) emulsified in CFA
followed 4 wk later with the same dose in PBS. None of the mice developed heart
TABLE II
Salivary Antibody Response Against M5 Protein in BALB/c Mice
Immunized Orally with S . typhimurium SL3261-pMK207
' Mice were injected with a booster dose ofpep M5 60 hbefore saliva collection.
Test serum IgA
ELISA titer"
IgG IgM
Percent
Type 5
opsonization
Type 24
Pre-immune <50 <50 <50 0 2
1 wk 100 200 <50 4 4
3 wk 400 400 <50 36 0
5 wk 800 800 <50 52 2
9 wk 100 1,600 200 90 2
10 wk 50 800 400 92 2
15 wk 100' 800 400 52 0
15 wk1 800 12,800 800 82 0
20 wk <50 400 200 10 2
20 wkt 400 3,200 200 80 2
Anti-pep M55 NDII ND ND 96 2
Anti-pep M245 ND ND ND 0 98
Test serum IgA
ELISA titer against pep M5
IgA + IgG + IgM
Pre-immune <4 <4
20 wk 32 32
20 wk + boost` 64 128POIRIER ET AL.
TABLE III
Challenge by Intra-peritoneal Injection ofM Type 5 and Type 24 Streptococci
or S. typhimurium SL1344 in BALBIc Mice Immunized Orally with Live aroA
S. typhimurium Transformed with pMK207 Expressing Type 5 M Protein
' Dose was determined as the CFU administered.
t Survival was recorded as thenumber of surviving mice divided by the num-
ber of mice challenged.
TABLE IV
Challenge by Intra-nasal Inoculation ofM Types 5 and 24 Streptococci
or S. typhimurium SL 1344 in BALBIc Mice Immunized Orally with
aroA S. typhimurium Transformed with pMK207 Expressing
Type 5 M Protein
' Challengedose wasdetermined as the CFUadministered intranasally and given
13 wk after the initial immunization (i.e., day 1).
t Survival was recorded as the number of surviving mice over the number of
mice challenged.
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crossreactive antibodies in sera obtained at 8 wk after the initial immunizing dose
eventhough the immuneresponses were strong asmeasured by ELISA against pep
M5 (ELISA titers = 12,800, 6,400, 6,400, and 3,200, respectively). These results
suggest that BALB/c mice may not recognize the autoimmune epitopes oftype 5
M protein.
Protective Immunity.
￿
Based onthese results, agroup ofmice immunized as above
were challenged on day 22 with type 5 or 24 streptococci, or virulentS typhimurium
SL1344. The mice inoculated with M5-producing SL3261-pMK207 were completely
protected against intraperitoneal challenges oftype 5 but not type 24 streptococci
Challenge
organisms Dose'
Surrnvalt
Unimmunized Immunized
M5 Streptococci 1.7 x 104 2/4 4/5
(Smith strain) 1.7 x 105 0/4 5/5
1.7 x 106 0/4 5/5
M24 Streptococci 1.6 x 103 1/3 1/3
(Vaughn strain) 1.6 x 104 0/3 0/3
1.6 x 105 0/3 0/3
S. typhimurium 7.3 x 101 0/3 3/3
(Strain S1,1344) 7.3 x 102 0/3 3/3
7.3 x 103 0/3 3/3
Challenge
organisms Dose'
Survivalt
Unimmunized Immunized
M5 Streptococci 3.9 x 10' 0/4 6/6
(Smith strain)
M24 Streptococci 3.5 x 10' 0/4 0/6
(Vaughn strain)
S. typhimurium 4.3 x 104 0/4 6/6
(strain SL1344)30
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(Table III); controlmice that were challenged with thevirulent S. typhimurium SL1344
also survived.
To test the efficacy oftheoral vaccineagainst mucosalinfections, agroupoforally
immunized BALB/c mice were challenged intranasally with type 5 or type 24 strep-
tococci, or with S typhimurium SL1344 (Table IV). Only the SL3261-pMK207-
immunized mice survived an intranasal inoculationof type 5 streptococci or virulent
S. typhimurium SL1344. Protection was M type specific; none of the mice challenged
with type 24 streptococci survived. These results indicatedthat the orally immunized
mice were protected against both parenteral and mucosal challenge infections with
group A streptococci bearingthe same serotype of M proteinexpressedby thetrans-
formed aroA strain of S typhimurium.
Discussion
In 1981, Hoiseth and Stocker(13) reported that the introduction of an auxotrophic
mutation such as aroA into the genome of a virulent strain ofS typhimuriumrendered
the organisms avirulent for mice. Such mutants are phenotypically dependent for
growth on several aromatic metabolites, including aromatic amino acids and en-
terochelin (13). Nevertheless, the organisms retain their ability to colonize and in-
vade theintestinal mucosa before they succumbto thelack ofthese required nutrients.
The short-lived invasion by the aroA mutants is sufficient to evoke protective immu-
nity against subsequent challenge infections with the virulent parenteral organisms.
More recently, Brown et al. (19) and Maskell et al. (20) investigated the use of
the aroA mutant strain of S typhimurium as a vehicle to deliver heterologous non-
Salmonella antigens to theimmune system in amanner that wouldstimulate mucosal
and hurnoral immune responses in experimental animals. In this way, antibodies
were raised against cloned 0-galactosidase by the oral administration ofaroA S. typh-
imuriumcarrying the cloned lacZstructural gene (19). Similarimmune responseswere
reported against theK88 antigen and the B fragment ofthelabile toxinofenterotox-
igenic E. coli in mice either injected intravenouslyor fed orally with aroA S typhimu-
rium expressing the respective cloned antigens (20).
We believe our results are the first to show that an antiphagocytic virulence deter-
minant can be cloned and stably expressed in these aroA organisms and, further,
that the oral administration of the transformed aroA mutant can evoke a protective
immune response againsttheunrelated bacterialpathogen. The protective immune
response was reflectednot only by thesurvival of theimmunizedanimalschallenged
with M type 5 streptococci, but also by the development of serumopsonicantibodies
and of mucosal M protein-specific IgA. Whether or not the antibodies against M
protein in the mucosal secretions had a role in protective immunity was not deter-
mined in thepresent investigation; the endpoint ofthe in vivo experimentswas death
and, therefore, the respective contributions of mucosal and humor-al immune re-
sponses to animal survival was not assessed in any direct way.
We were unable to draw any conclusions concerning the recognition ofMprotein
autoimmune epitopes in the recombinant vaccine administered by the oral route.
BALB/c mice immunized with M protein emulsified in CFA by the subcutaneous
route also failed to develop crossreactive antibodies, suggesting that this animal spe-
cies may not be capable of recognizing the autoimmune epitopes of streptococcal
M protein.POIRIER ET AL.
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Interestingly, our cell fractionation studies indicated that most of the Mprotein
produced by the S. typhimurium mutant remained in the cytoplasmic compartment
even though M protein is secreted into the paraplasmic space when cloned and ex-
pressed in E. coli (18). Thus, the protective immune response against this particular
virulence factor does not require periplasmic or surface expression for recognition
by the immune system. Our findings are consistent with those of Brown et al. (19)
who successfully produced immune responses to cloned S-galactosidase, a protein
known to be confined to the cytoplasmic space.
Plasmid replication and the expression of the Mprotein encoded by the cloned
spm5 gene appeared to be stable both in vitro and in vivo in theabsenceofantibiotic
pressure. Because of the high degree of stability, this plasmid is a good candidate
for use in the design of multivalent vaccines, whereby the spm5 gene is used as a
carrierfor thetandem fusion ofnatural or synthetic oligonucleotides encoding viru-
lence determinants of a number of different M serotypes of group A streptococci
or other infectious agents. That tandem hybrid peptides are effective as multivalent
protective vaccines has alreadybeen demonstrated in ourlaboratories (11, 12). Thus,
ourfindings provide an approach for the genetic engineeringofmultivalent Mpro-
tein vaccines to protect against many serotypes of S. pyogenes infections, especially
against those strains causingpoststreptococcal rheumaticfeverandglomerulonephritis.
Summary
Attenuated strains of Salmonella have been used effectively as vaccines against ty-
phoidfever. We have investigated the use of such strains to delivercloned antiphago-
cytic virulencedeterminants ofunrelatedbacteria. The aroA strain of S. typhimurium
SL3261 was transformed with alow-copy plasmid vector pMK207, which contains
the cloned gene spm5 encoding streptococcal Mprotein, the majorvirulence factor
of these organisms. The transformed SL3261 expressed type 5 M protein in the
cytoplasmic fraction, and when fed orally to BALB/c mice, evoked both serum and
salivary IgA, IgG, and IgMantibodies directed againsttype 5 M protein. The orally
immunizedmice were completely protectedagainstboth intranasal andintraperitoneal
challenge infections with virulent S typhimurium SL1344 or M5 streptococci. These
studies provide evidence that an attenuated strain of Salmonella can be used effec-
tively as a general vaccine vehicle to deliver antiphagocytic virulence determinants
of unrelated bacteria.
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